Outcomes of hyaluronan therapy in diabetic foot wounds

J. R. Vazquez, Brian Short, Andrew H. Findlow, Brent P. Nixon, Andrew J M Boulton, David G Armstrong

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The purpose of this study was to evaluate outcomes of persons with neuropathic diabetic foot wounds treated with a hyaluronan-containing dressing. Data were abstracted for 36 patients with diabetes, 72.2% male, aged 60.0±10.7 years and a mean glycated hemoglobin (HbA1c) of 9.5±2.5% presenting for care at two large, multidisciplinary wound care centers. All patients received surgical debridement for their diabetic foot wounds and were placed on therapy consisting of hyaluronan dressing (Hyalofill®, Convatec, USA) with dressing changes taking place every other day. Outcomes evaluated included time to complete wound closure and proportion of patients achieving wound closure in 20 weeks. Hyalofill® therapy was used until the wound bed achieved 100% granulation tissue. Therapy was then followed by a moisture-retentive dressing until complete epithelialization. In total, 75.0% of wounds measuring a mean 2.2±2.2 cm2 healed in the 20-week evaluation period. Of those that healed in this period, healing took place in a mean 10.0±4.8 weeks. The average duration of Hyalofill® therapy in all patients was 8.6±4.2 weeks. Deeper (UT Grade 2A) wounds were over 15 times less likely to heal than superficial (1A) wounds (94.7 vs. 52.9%, Odds Ratio=15.9, 95% Confidence Interval=1.7-142.8, P=0.006). We conclude that a regimen consisting of moist wound healing using hyaluronan-containing dressings may be a useful adjunct to appropriate diabetic foot ulcer care. We await the completion of a multicenter randomized controlled trial in this area to either support or refute this initial assessment.

Original languageEnglish (US)
Pages (from-to)123-127
Number of pages5
JournalDiabetes Research and Clinical Practice
Volume59
Issue number2
DOIs
StatePublished - Feb 1 2003
Externally publishedYes

Fingerprint

Diabetic Foot
Hyaluronic Acid
Bandages
Wounds and Injuries
Therapeutics
Granulation Tissue
Glycosylated Hemoglobin A
Debridement
Wound Healing
Randomized Controlled Trials
Odds Ratio
Confidence Intervals

Keywords

  • Amputation
  • Diabetes
  • Foot
  • Ulcer
  • Wound

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Outcomes of hyaluronan therapy in diabetic foot wounds. / Vazquez, J. R.; Short, Brian; Findlow, Andrew H.; Nixon, Brent P.; Boulton, Andrew J M; Armstrong, David G.

In: Diabetes Research and Clinical Practice, Vol. 59, No. 2, 01.02.2003, p. 123-127.

Research output: Contribution to journalArticle

Vazquez, J. R. ; Short, Brian ; Findlow, Andrew H. ; Nixon, Brent P. ; Boulton, Andrew J M ; Armstrong, David G. / Outcomes of hyaluronan therapy in diabetic foot wounds. In: Diabetes Research and Clinical Practice. 2003 ; Vol. 59, No. 2. pp. 123-127.
@article{4033c203f49d47d6b2f29aa2173534d4,
title = "Outcomes of hyaluronan therapy in diabetic foot wounds",
abstract = "The purpose of this study was to evaluate outcomes of persons with neuropathic diabetic foot wounds treated with a hyaluronan-containing dressing. Data were abstracted for 36 patients with diabetes, 72.2{\%} male, aged 60.0±10.7 years and a mean glycated hemoglobin (HbA1c) of 9.5±2.5{\%} presenting for care at two large, multidisciplinary wound care centers. All patients received surgical debridement for their diabetic foot wounds and were placed on therapy consisting of hyaluronan dressing (Hyalofill{\circledR}, Convatec, USA) with dressing changes taking place every other day. Outcomes evaluated included time to complete wound closure and proportion of patients achieving wound closure in 20 weeks. Hyalofill{\circledR} therapy was used until the wound bed achieved 100{\%} granulation tissue. Therapy was then followed by a moisture-retentive dressing until complete epithelialization. In total, 75.0{\%} of wounds measuring a mean 2.2±2.2 cm2 healed in the 20-week evaluation period. Of those that healed in this period, healing took place in a mean 10.0±4.8 weeks. The average duration of Hyalofill{\circledR} therapy in all patients was 8.6±4.2 weeks. Deeper (UT Grade 2A) wounds were over 15 times less likely to heal than superficial (1A) wounds (94.7 vs. 52.9{\%}, Odds Ratio=15.9, 95{\%} Confidence Interval=1.7-142.8, P=0.006). We conclude that a regimen consisting of moist wound healing using hyaluronan-containing dressings may be a useful adjunct to appropriate diabetic foot ulcer care. We await the completion of a multicenter randomized controlled trial in this area to either support or refute this initial assessment.",
keywords = "Amputation, Diabetes, Foot, Ulcer, Wound",
author = "Vazquez, {J. R.} and Brian Short and Findlow, {Andrew H.} and Nixon, {Brent P.} and Boulton, {Andrew J M} and Armstrong, {David G}",
year = "2003",
month = "2",
day = "1",
doi = "10.1016/S0168-8227(02)00197-3",
language = "English (US)",
volume = "59",
pages = "123--127",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Outcomes of hyaluronan therapy in diabetic foot wounds

AU - Vazquez, J. R.

AU - Short, Brian

AU - Findlow, Andrew H.

AU - Nixon, Brent P.

AU - Boulton, Andrew J M

AU - Armstrong, David G

PY - 2003/2/1

Y1 - 2003/2/1

N2 - The purpose of this study was to evaluate outcomes of persons with neuropathic diabetic foot wounds treated with a hyaluronan-containing dressing. Data were abstracted for 36 patients with diabetes, 72.2% male, aged 60.0±10.7 years and a mean glycated hemoglobin (HbA1c) of 9.5±2.5% presenting for care at two large, multidisciplinary wound care centers. All patients received surgical debridement for their diabetic foot wounds and were placed on therapy consisting of hyaluronan dressing (Hyalofill®, Convatec, USA) with dressing changes taking place every other day. Outcomes evaluated included time to complete wound closure and proportion of patients achieving wound closure in 20 weeks. Hyalofill® therapy was used until the wound bed achieved 100% granulation tissue. Therapy was then followed by a moisture-retentive dressing until complete epithelialization. In total, 75.0% of wounds measuring a mean 2.2±2.2 cm2 healed in the 20-week evaluation period. Of those that healed in this period, healing took place in a mean 10.0±4.8 weeks. The average duration of Hyalofill® therapy in all patients was 8.6±4.2 weeks. Deeper (UT Grade 2A) wounds were over 15 times less likely to heal than superficial (1A) wounds (94.7 vs. 52.9%, Odds Ratio=15.9, 95% Confidence Interval=1.7-142.8, P=0.006). We conclude that a regimen consisting of moist wound healing using hyaluronan-containing dressings may be a useful adjunct to appropriate diabetic foot ulcer care. We await the completion of a multicenter randomized controlled trial in this area to either support or refute this initial assessment.

AB - The purpose of this study was to evaluate outcomes of persons with neuropathic diabetic foot wounds treated with a hyaluronan-containing dressing. Data were abstracted for 36 patients with diabetes, 72.2% male, aged 60.0±10.7 years and a mean glycated hemoglobin (HbA1c) of 9.5±2.5% presenting for care at two large, multidisciplinary wound care centers. All patients received surgical debridement for their diabetic foot wounds and were placed on therapy consisting of hyaluronan dressing (Hyalofill®, Convatec, USA) with dressing changes taking place every other day. Outcomes evaluated included time to complete wound closure and proportion of patients achieving wound closure in 20 weeks. Hyalofill® therapy was used until the wound bed achieved 100% granulation tissue. Therapy was then followed by a moisture-retentive dressing until complete epithelialization. In total, 75.0% of wounds measuring a mean 2.2±2.2 cm2 healed in the 20-week evaluation period. Of those that healed in this period, healing took place in a mean 10.0±4.8 weeks. The average duration of Hyalofill® therapy in all patients was 8.6±4.2 weeks. Deeper (UT Grade 2A) wounds were over 15 times less likely to heal than superficial (1A) wounds (94.7 vs. 52.9%, Odds Ratio=15.9, 95% Confidence Interval=1.7-142.8, P=0.006). We conclude that a regimen consisting of moist wound healing using hyaluronan-containing dressings may be a useful adjunct to appropriate diabetic foot ulcer care. We await the completion of a multicenter randomized controlled trial in this area to either support or refute this initial assessment.

KW - Amputation

KW - Diabetes

KW - Foot

KW - Ulcer

KW - Wound

UR - http://www.scopus.com/inward/record.url?scp=0037304927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037304927&partnerID=8YFLogxK

U2 - 10.1016/S0168-8227(02)00197-3

DO - 10.1016/S0168-8227(02)00197-3

M3 - Article

C2 - 12560161

AN - SCOPUS:0037304927

VL - 59

SP - 123

EP - 127

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 2

ER -